Drug Profile
Research programme: deubiquitinating enzyme inhibitors - MISSION Therapeutics
Alternative Names: DUB inhibitors - MISSION Therapuetics; Ubiquitin C-terminal hydrolase 1 inhibitors - MISSION Therapeutics; Ubiquitin-specific protease 10 inhibitors - MISSION Therapeutics; Ubiquitin-specific protease 30 inhibitors - MISSION Therapeutics; UCHL1 inhibitors - MISSION Therapeutics; USP10 inhibitors - MISSION Therapeutics; USP30 inhibitors - MISSION TherapeuticsLatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator MISSION Therapeutics
- Class Antifibrotics; Antineoplastics; Neuroprotectants; Small molecules; Urologics
- Mechanism of Action Deubiquitinating enzyme inhibitors; Ubiquitin-specific protease inhibitors; Usp30 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute kidney injury; Mitochondrial myopathies
- No development reported Fibrosis; Idiopathic pulmonary fibrosis; Mitochondrial disorders; Neurodegenerative disorders
- Discontinued Cancer; Ovarian cancer
Most Recent Events
- 28 Dec 2022 No recent reports of development identified for preclinical development in Idiopathic-pulmonary-fibrosis in United Kingdom
- 28 Dec 2022 No recent reports of development identified for preclinical development in Mitochondrial disorders in United Kingdom
- 28 Dec 2022 No recent reports of development identified for preclinical development in Neurodegenerative-disorders in United Kingdom